Gastroenterology

  • Home
  • Gastroenterology
Headache Relief Shampoo Voted #1 Best New Product in 2019

Dr. D’s Medicated Headache Relief Shampoo is now available. This medicated shampoo will help alleviate headaches simply by soaking it on your head. Finding relief from minor to severe headaches shouldn’t always involve reaching for a bottle of pills. Dr. D is here to give you another option. Our proprietary formula will leave your head feeling better.

BUY NOW! http://headachereliefshampoo.com/product/headache-relief-shampoo/

January 1, 2019 / by / in
Gastric Ultrasound
Condition:   Surgery
Intervention:   Device: Point-of-Care Ultrasound
Sponsor:   Alok Moharir
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 24, 2020 / by / in
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Conditions:   Neoplasms;   Melanoma;   Non Small Cell Lung Cancer (NSCLC);   Head and Neck Squamous Cell Carcinoma (HNSCC);   Renal Cell Carcinoma (RCC);   Urothelial Neoplasm;   Hepatocellular Carcinoma (HCC);   Microsatellite Instability-high or Mismatch Repair Deficient (MSI-H/dMMR);   Colorectal Cancer;   Gastroesophageal Junction Adenocarcinoma;   Gastric Cancer;   Cervical Cancer;   Primary Peritoneal Cancer;   Platinum-resistant Ovarian Cancer (PROC);   Serous Epithelial Ovarian Cancer;   Fallopian Tube Cancer
Interventions:   Drug: DSP-7888 Dosing Emulsion;   Drug: Nivolumab;   Drug: Pembrolizumab
Sponsor:   Boston Biomedical, Inc
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 23, 2020 / by / in
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Conditions:   Radiotherapy;   Immunotherapy;   Microsatellite Instability-High Solid Malignant Tumour;   Metastasis From Malignant Tumor of Stomach (Disorder);   Squamous Cell Carcinoma of Head and Neck;   Metastasis From Malignant Tumor of Cervix;   Metastatic Squamous Cell Carcinoma;   Metastasis From Malignant Melanoma of Skin (Disorder);   Merkel Cell Carcinoma (Disorder);   Metastasis From Malignant Tumor of Lung;   Metastasis From Malignant Tumor of Bladder (Disorder)
Intervention:   Drug: NBTXR3
Sponsor:   Nanobiotix
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 22, 2020 / by / in
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Conditions:   Breast Cancer;   Head and Neck Squamous Cell Carcinoma;   Non Small Cell Lung Cancer;   Hepatocellular Cancer;   Colorectal Cancer;   Gastric Adenocarcinoma;   Melanoma;   Advanced Cancer
Intervention:   Drug: TTI-101
Sponsors:   Tvardi Therapeutics, Incorporated;   M.D. Anderson Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 22, 2020 / by / in
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
Condition:   Locally Advanced or Metastatic Solid Tumors
Interventions:   Drug: BGB-290;   Drug: Temozolomide
Sponsors:   BeiGene;   Myriad Genetics, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 19, 2020 / by / in
Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer
Condition:   Gastric and Gastroesophageal Junction Cancer
Intervention:   Drug: AMG 199
Sponsor:   Amgen
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 16, 2020 / by / in
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Conditions:   Gastric Cancer;   Esophageal Cancer;   GastroEsophageal Cancer
Interventions:   Drug: Nivolumab;   Drug: Relatlimab;   Drug: Carboplatin;   Drug: Paclitaxel;   Radiation: Radiation
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Bristol-Myers Squibb
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 16, 2020 / by / in
G-POEM for Treatment of Refractory Gastroparesis
Conditions:   Diabetic Gastroparesis;   Idiopathic Gastroparesis;   Gastroparesis Postoperative
Intervention:   Procedure: Gastric Per Oral Endoscopic Myotomy
Sponsor:   Johns Hopkins University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 10, 2020 / by / in
The Use Of Domperidone For The Relief Of Refractory Upper Gastrointestinal GI Symptoms
Condition:   Gastroparesis
Intervention:   Drug: Domperidone
Sponsor:   Yale University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 8, 2020 / by / in
IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer
Conditions:   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVB Gastric Cancer AJCC v8;   Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Metastatic Gastric Adenocarcinoma;   Metastatic Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IV Gastric Cancer AJCC v8;   Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8;   Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Recurrent Gastric Adenocarcinoma;   Recurrent Gastroesophageal Junction Adenocarcinoma
Interventions:   Drug: Cyclophosphamide;   Biological: Cytokine-based Biologic Agent IRX-2;   Biological: Pembrolizumab
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 4, 2020 / by / in